Prashant Jay Ruchaya

Dr. Prashant Jay Ruchaya

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2016 in International Journal of Cardiology
Verified
Journal Article
Closed access
DRDomenico G. Della Rocca
Domenico G. Della Rocca
BWBradley J. Willenberg
Bradley J. Willenberg
YQYanfei Qi
Yanfei Qi
CSChelsey S. Simmons
Chelsey S. Simmons
ARAndres Rubiano
Andres Rubiano
CPCarl J Pepine
Carl J Pepine

15 October 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
IKIoannis Kokkinopoulos
Ioannis Kokkinopoulos
HIHidekazu Ishida
Hidekazu Ishida
RSRie Saba
Rie Saba
PRPrashant Jay Ruchaya
Prashant Jay Ruchaya
CCClaudia Cabrera
Claudia Cabrera
KYKenta Yashiro
Kenta Yashiro
In the early vertebrate embryo, cardiac progenitor/precursor cells (CPs) give rise to cardiac structures. Better understanding their biological character is critical to understand the heart development and to apply CPs for the clinical arena. However, our knowledge remains incomplete. With the use of single-cell expression profiling, we have now revealed rapid and dynamic changes in gene expression profiles of the embryonic CPs during the early phase after their segregation from the cardiac mesoderm. Progressively, the nascent mesodermal gene Mesp1 terminated, and Nkx2-5+/Tbx5+ population rapidly replaced the Tbx5low+ population as the expression of the cardiac genes Tbx5 and Nkx2-5 increased. At the Early Headfold stage, Tbx5-expressing CPs gradually showed a unique molecular signature with signs of cardiomyocyte differentiation. Lineage-tracing revealed a developmentally distinct characteristic of this population. They underwent progressive differentiation only towards the cardiomyocyte lineage corresponding to the first heart field rather than being maintained as a progenitor pool. More importantly, Tbx5 likely plays an important role in a transcriptional network to regulate the distinct character of the FHF via a positive feedback loop to activate the robust expression of Tbx5 in CPs. These data expands our knowledge on the behavior of CPs during the early phase of cardiac development, subsequently providing a platform for further study.

1 July 2016 in Cell Reports
Verified
Journal Article
Open access
HIHidekazu Ishida
Hidekazu Ishida
RSRie Saba
Rie Saba
IKIoannis Kokkinopoulos
Ioannis Kokkinopoulos
MHMasakazu Hashimoto
Masakazu Hashimoto
OYOsamu Yamaguchi
Osamu Yamaguchi
KYKenta Yashiro
Kenta Yashiro
A surface marker that distinctly identifies cardiac progenitors (CPs) is essential for the robust isolation of these cells, circumventing the necessity of genetic modification. Here, we demonstrate that a Glycosylphosphatidylinositol-anchor containing neurotrophic factor receptor, Glial cell line-derived neurotrophic factor receptor alpha 2 (Gfra2), specifically marks CPs. GFRA2 expression facilitates the isolation of CPs by fluorescence activated cell sorting from differentiating mouse and human pluripotent stem cells. Gfra2 mutants reveal an important role for GFRA2 in cardiomyocyte differentiation and development both in vitro and in vivo. Mechanistically, the cardiac GFRA2 signaling pathway is distinct from the canonical pathway dependent on the RET tyrosine kinase and its established ligands. Collectively, our findings establish a platform for investigating the biology of CPs as a foundation for future development of CP transplantation for treating heart failure.

1 December 2016 in Neuropeptides
Verified
Journal Article
Closed access
PRPrashant Jay Ruchaya
Prashant Jay Ruchaya
GSGuilherme F. Speretta
Guilherme F. Speretta
GBGraziela Torres Blanch
Graziela Torres Blanch
HLHongwei Li
Hongwei Li
CSColin Sumners
Colin Sumners
DCDébora S.A. Colombari
Débora S.A. Colombari

31 January 2017 in American Journal of Hypertension
Verified
Journal Article
Open access
PDF file
RBRafaela Moreira Barbosa
Rafaela Moreira Barbosa
GSGuilherme F. Speretta
Guilherme F. Speretta
DDDaniel Penteado Martins Dias
Daniel Penteado Martins Dias
PRPrashant Jay Ruchaya
Prashant Jay Ruchaya
HLHongwei Li
Hongwei Li
DCDébora S. A. Colombari
Débora S. A. Colombari
Macrophage migration inhibitory factor (MIF) is an intracellular inhibitory regulator of the actions of angiotensin II in the central nervous system. Renovascular hypertensive 2-kidney, 1-clip (2K1C) rats have an increased activity of the renin–angiotensin system and a decrease in baroreflex function compared to normotensive (NT) rats. In the present study, we tested the effects of MIF overexpression within the nucleus of the solitary tract (NTS), a key brainstem region for cardiovascular regulation, on the development of hypertension, on baroreflex function, and on water and food intake in 2K1C rats. Holtzman NT rats received a silver clip around the left renal artery to induce 2K1C hypertension. Three weeks later, rats were microinjected in the NTS with AAV2-CBA-MIF, to increase the expression of MIF, or with the control vector AAV2-CBA-enhanced green fluorescent protein. Mean arterial pressure (MAP) and heart rate were recorded by telemetry. Baroreflex function was tested, and water and food intake were also measured. Increasing MIF expression in the NTS of 2K1C rats attenuated the development of hypertension, reversed the impairment of baroreflex function, and reduced the increase in water intake. In contrast to 2K1C rats, similar increases in MIF expression in the NTS of NT rats produced no changes in baseline MAP, baroreflex function, or water intake. These results indicate that an increased expression of MIF within the NTS attenuates the development of hypertension and restores the baroreflex function in 2K1C rats.

23 October 2013 in Experimental Physiology
Verified
Journal Article
Open access
PDF file
PRPrashant Jay Ruchaya
Prashant Jay Ruchaya
VAVagner Roberto Antunes
Vagner Roberto Antunes
JPJ. F. R. Paton
J. F. R. Paton
DMD. Murphy
D. Murphy
SYS. T. Yao
S. T. Yao
New Findings: What is the central question of this study?The chemokine fractalkine (FKN) and its cognate receptor, CX3CR1, are expressed in the brain, but their distribution and function within the paraventricular nucleus of the hypothalamus (PVN) have not been previously investigated. What is the main finding and its importance?We show that both FKN and CX3CR1 receptor mRNA and protein are expressed in the PVN and that FKN elicits hypotension and tachycardia when exogeneously applied by microinjection, an effect that is attenuated in rats with heart failure. These findings are important because they demonstrate that FKN and its cognate receptor are expressed and play a role in controlling cardiovascular function within the PVN. The paraventricular nucleus (PVN) of the hypothalamus plays an important role in the regulation of sympathetic nerve activity, which is significantly elevated in chronic heart failure (CHF). Fractalkine (FKN) and its cognate receptor, CX3CR1, are constitutively expressed in the central nervous system, but their role and physiological significance are not well known. The aims of the present study were to determine whether FKN plays a cardiovascular role within the PVN and to investigate how the actions of FKN might be altered in CHF. We show that both FKN and CX3CR1 are expressed on neurons in the PVN of rats, suggesting that they may have a physiological function in this brain nucleus. Unilateral microinjection of FKN directly into the PVN of anaesthetized rats elicited a significant dose‐related decrease in blood pressure (1.0 nmol, −5 ± 3 mmHg; 2.5 nmol, −13 ± 2 mmHg; 5.0 nmol, −22 ± 3 mmHg; and 7.5 nmol, −32 ± 3 mmHg) and a concomitant increase in heart rate (1.0 nmol, 6 ± 3 beats min−1; 2.5 nmol, 11 ± 3 beats min−1; 5 nmol, 18 ± 4 beats min−1; and 7.5 nmol, 27 ± 5 beats min−1) compared with control saline microinjections. In order to determine whether FKN signalling is altered in rats with CHF, we first performed quantitative RT‐PCR and Western blot analysis and followed these experiments with functional studies in rats with CHF and sham‐operated control rats. We found a significant increase in CX3CR1 mRNA and protein expression, as determined by quantitative RT‐PCR and Western blot analysis, respectively, in the PVN of rats with CHF compared with sham‐operated control rats. We also found that the blood pressure effects of FKN (2.5 nmol in 50 nl) were significantly attenuated in rats with CHF (change in mean arterial pressure, −6 ± 3 mmHg) compared with sham‐operated control rats (change in mean arterial pressure, −16 ± 6 mmHg). These data suggest that FKN and its receptor, CX3CR1, modulate cardiovascular function at the level of the PVN and that the actions of FKN within this nucleus are altered in heart failure.